Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): A meta-analysis

International Journal of Neuropsychopharmacology

Volumn 12, Issue 8, 2009, Pages 1137-1147

  Mészáros, Ágnes ^a   Czobor, Pál ^a,b   Bálint, Sára ^a   Komlósi, Sarolta ^a   Simon, Viktória ^a   Bitter, István ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

ADHD; Adult; Clinical trial; Non stimulants; Pharmacotherapy; Stimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DESIPRAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO;

ATTENTION DEFICIT DISORDER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 69749114967     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990198     Document Type: Review

References (53)

1. Adler LA, Goodman DW, Kollins SH, Weisler RH, et al. (2008). Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 69, 1364-1374.
2. Alpert JE, Maddocks A, Nierenberg AA, OSullivan R, et al. (1996). Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Research 62, 213-219.
3. Anderson IM (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36.
4. Arnsten AF, Scahill L, Findling RL (2007). Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. Journal of Child and Adolescent Psychopharmacology 17, 393-406.
5. Ballon JS, Feifel D (2006). A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 67, 554-566.
6. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004). Non-stimulant medications in the treatment of ADHD. European Child & Adolescent Psychiatry 13, I102-I116.
7. Begg CB, Mazumdar M (1994). Operating characteristics of a bank correlation test for publication bias. Biometrics 50, 1088-1101.
8. Biederman J, Mick E, Faraone SV (2000). Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. American Journal of Psychiatry 157, 816-818.
9. Biederman J, Mick E, Faraone S, Hammerness P, et al. (2006). A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder - a pilot study. Journal of Clinical Psychopharmacology 26, 163-166.
10. Biederman J, Monuteaux MC, Spencer T, Wilens T, et al. (2008). Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. American Journal of Psychiatry 165, 597-603.
11. Biederman J, Spencer T (2000). Non-stimulant treatments for ADHD. European Child & Adolescent Psychiatry 9, 51-59.
12. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Hillsdale: Lawrence Erlbaum Associates, Inc.
13. Conners CK (1998). Rating scales in attention-deficit/ hyperactivity disorder: use in assessment and treatment monitoring. Journal of Clinical Psychiatry 59, 24-30.
14. Conners CK (1999). Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatric Clinics of North America 46, 857-870.
15. Corman SL, Fedutes BA, Culley CM (2004). Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. American Journal of Health-System Pharmacy 61, 2391-2399.
16. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553-564.
17. DerSimonian R, Laird N (1986). Metaanalysis in clinical-trials. Controlled Clinical Trials 7, 177-188.
18. Dodson WW (2005). Pharmacotherapy of adult ADHD. Journal of Clinical Psychology 61, 589-606.
19. Dupaul G, Power T, Anastapoulos A, Reid R (1998). ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford.
20. Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine 8, 4-8.
21. Faraone SV, Wilens T (2003). Does stimulant treatment lead to substance use disorders? Journal of Clinical Psychiatry 64, 9-13.
22. Faries D, Herrera J, Rayamajhi J, DeBrota D, et al. (2000). The responsiveness of the Hamilton Depression Rating Scale. Journal of Psychiatric Research 34, 3-10.
23. Gibson AP, Bettinger TL, Patel NC, Crismon ML (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Annals of Pharmacotherapy 40, 1134-1142.
24. Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998). Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Journal of the American Medical Association 279, 1100-1107.
25. Henningfield JE, Fant RV, Buchhalter AR, Stitzer AL (2005). Pharmacotherapy for nicotine dependence. CA: A Cancer Journal for Clinicians 55, 281-299.
26. Kessler RC, Adler L, Barkley R, Biederman J, et al. (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry 163, 716-723.
27. Kollins SH, MacDonald EK, Rush CR (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects - a review. Pharmacology Biochemistry and Behavior 68, 611-627.
28. Leucht S, Corves C, Arbter D, Engel RR, et al. (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
29. Leucht S, Komossa K, Rummel-Kluge C, Corves C, et al. (2009b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152-163.
30. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
31. MacGillivray S, Arroll B, Hatcher S, Ogston S, et al. (2003). Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. British Medical Journal 326, 1014-1017.
32. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1998). Adult psychiatric status of hyperactive boys grown up. American Journal of Psychiatry 155, 493-498.
33. Mannuzza S, Klein RG, Truong NL, Moulton JL, et al. (2008). Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. American Journal of Psychiatry 165, 604-609.
34. Michelson D, Adler L, Spencer T, Reimherr FW, et al. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry 53, 112-120.
35. Mick E, Biederman J, Spencer T, Faraone SV, Zhang H (2006). The validity of the quality of life enjoyment and satisfaction questionnaire in adults with ADHD [Meeting abstract]. European Neuropsychopharmacology 16, S533.
36. Moran-Gates T, Zhang K, Baldessarini RJ, Tarazi FI (2005). Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology 8, 439-444.
37. National Institute of Mental Health (NIMH) (1985). CGI (Clinical Global Impression Scale). Psychopharmacological Bulletin 4, 839-844.
38. Newhouse PA, Potter A, Singh A (2004). Effects of nicotinic stimulation on cognitive performance. Current Opinion in Pharmacology 4, 36-46.
39. Parker G, Brotchie H, Fletcher K (2006). An increased proportional representation of bipolar disorder of younger depressed patients: analysis of two clinical databases. Journal of Affective Disorders 95, 141-144.
40. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z (1999). A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry 33, 494-502.
41. Potter AS, Newhouse PA (2008). Acute nicotine improves cognitive deficits in young adults with attention-deficit/ hyperactivity disorder. Pharmacology Biochemistry and Behavior 88, 407-417.
42. Rezvani AH, Levin ED (2001). Cognitive effects of nicotine. Biological Psychiatry 49, 258-267.
43. Simon V, Czobor P, Balint S, Meszaros A, et al. (2007). Detailed review of epidemiologic studies on adult attention deficit/hyperactivity disorder (ADHD). Psychiatrica Hungarica 22, 4-19.
44. Spencer T, Biederman J, Wilens T, Faraone S, et al. (2001). Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Archives of General Psychiatry 58, 775-782.
45. van Houwelingen HC, Arends LR, Stijnen T (2002). Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 21, 589-624.
46. Volkow ND, Swanson JM (2008). Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? American Journal of Psychiatry 165, 553-555.
47. Ward MF, Wender PH, Reimherr FW (1993). The Wender Utah Rating-Scale - an aid in the retrospective diagnosis of childhood attention-deficit hyperactivity disorder. American Journal of Psychiatry 150, 885-890.
48. Weiss S, Nosten-Bertr M, McIntosh JM, Giros B, Martres MP (2007). Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 32, 2465-2478.
49. Wilens TE, Biederman J, Prince J, Spencer TJ, et al. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. American Journal of Psychiatry 153, 1147-1153.
50. Wilens TE, Decker MW (2007). Neuronal nicotinic receptor agonists for the treatment of attention-deficit/ hyperactivity disorder: focus on cognition. Biochemical Pharmacology 74, 1212-1223.
51. Wilens TE, Spencer TJ, Biederman J, Girard K, et al. (2001). A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry 158, 282-288.
52. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA (2006). ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biological Psychiatry 59, 1065-1070.
53. Woods SW, Stolar M, Sernyak MJ, Charney DS (2001). Consistency of atypical antipsychotic superiority to placebo in recent clinical trials. Biological Psychiatry 49, 64-70.